Neuland Laboratories Ltd
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]
- Market Cap ₹ 9,670 Cr.
- Current Price ₹ 7,537
- High / Low ₹ 7,794 / 1,980
- Stock P/E 30.5
- Book Value ₹ 883
- Dividend Yield 0.13 %
- ROCE 20.8 %
- ROE 17.9 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 68.3% CAGR over last 5 years
Cons
- Stock is trading at 8.54 times its book value
- Promoter holding is low: 32.7%
- Company has a low return on equity of 12.1% over last 3 years.
- Promoter holding has decreased over last 3 years: -3.48%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
448 | 461 | 466 | 469 | 510 | 579 | 527 | 667 | 763 | 937 | 951 | 1,191 | 1,581 | |
401 | 402 | 395 | 402 | 430 | 472 | 477 | 608 | 661 | 790 | 807 | 918 | 1,105 | |
Operating Profit | 47 | 58 | 71 | 67 | 80 | 106 | 51 | 58 | 102 | 147 | 144 | 273 | 476 |
OPM % | 11% | 13% | 15% | 14% | 16% | 18% | 10% | 9% | 13% | 16% | 15% | 23% | 30% |
2 | 3 | 3 | 0 | 2 | 1 | 4 | 3 | 4 | 16 | 0 | 9 | 15 | |
Interest | 33 | 31 | 25 | 27 | 24 | 21 | 19 | 16 | 22 | 18 | 14 | 13 | 15 |
Depreciation | 15 | 15 | 15 | 15 | 16 | 19 | 22 | 26 | 31 | 40 | 49 | 53 | 57 |
Profit before tax | 1 | 16 | 35 | 25 | 42 | 67 | 14 | 20 | 53 | 105 | 82 | 216 | 419 |
Tax % | -210% | 12% | 23% | 36% | 36% | 30% | 13% | 19% | 69% | 23% | 22% | 24% | |
3 | 14 | 27 | 16 | 27 | 47 | 12 | 16 | 16 | 81 | 64 | 164 | 317 | |
EPS in Rs | 2.88 | 15.57 | 30.12 | 17.96 | 30.75 | 52.74 | 13.57 | 12.81 | 12.63 | 62.85 | 49.74 | 127.45 | 247.12 |
Dividend Payout % | -0% | 7% | 9% | 8% | 7% | -0% | -0% | -0% | 16% | 8% | 10% | 8% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 18% |
3 Years: | 16% |
TTM: | 52% |
Compounded Profit Growth | |
---|---|
10 Years: | 29% |
5 Years: | 68% |
3 Years: | 117% |
TTM: | 215% |
Stock Price CAGR | |
---|---|
10 Years: | 40% |
5 Years: | 60% |
3 Years: | 44% |
1 Year: | 277% |
Return on Equity | |
---|---|
10 Years: | 9% |
5 Years: | 9% |
3 Years: | 12% |
Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5 | 8 | 8 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 13 | 13 |
Reserves | 71 | 92 | 116 | 152 | 178 | 537 | 549 | 686 | 697 | 774 | 828 | 981 | 1,120 |
220 | 211 | 190 | 188 | 182 | 192 | 319 | 231 | 264 | 182 | 241 | 128 | 101 | |
130 | 114 | 169 | 162 | 155 | 148 | 194 | 200 | 257 | 356 | 302 | 457 | 431 | |
Total Liabilities | 426 | 425 | 483 | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,665 |
151 | 136 | 131 | 123 | 139 | 466 | 475 | 542 | 653 | 716 | 767 | 758 | 800 | |
CWIP | 27 | 36 | 35 | 41 | 40 | 20 | 126 | 104 | 24 | 17 | 20 | 41 | 12 |
Investments | 7 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 7 | 4 | 1 | 0 |
240 | 246 | 311 | 340 | 337 | 393 | 463 | 476 | 547 | 585 | 592 | 781 | 853 | |
Total Assets | 426 | 425 | 483 | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,665 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
49 | 26 | 49 | 13 | 45 | 39 | 11 | 70 | 57 | 189 | 60 | 237 | |
-5 | -7 | -10 | -14 | -20 | -42 | -116 | -77 | -49 | -84 | -95 | -61 | |
-44 | -20 | -39 | 1 | -24 | -0 | 105 | 12 | -5 | -114 | 38 | -136 | |
Net Cash Flow | 0 | -1 | -0 | 0 | 1 | -4 | -0 | 5 | 3 | -9 | 3 | 40 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 78 | 78 | 93 | 100 | 85 | 114 | 134 | 90 | 91 | 85 | 90 | 111 |
Inventory Days | 118 | 124 | 138 | 170 | 182 | 186 | 266 | 191 | 209 | 205 | 227 | 211 |
Days Payable | 141 | 110 | 139 | 167 | 121 | 118 | 189 | 118 | 110 | 126 | 100 | 129 |
Cash Conversion Cycle | 55 | 92 | 92 | 103 | 147 | 182 | 211 | 162 | 190 | 164 | 216 | 193 |
Working Capital Days | 51 | 76 | 89 | 124 | 115 | 139 | 176 | 126 | 131 | 93 | 124 | 96 |
ROCE % | 11% | 15% | 19% | 16% | 18% | 16% | 4% | 4% | 8% | 11% | 10% | 21% |
Documents
Announcements
- Board Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2024, And; To Recommend Final Dividend, If Any, For The Financial Year Ended March 31, 2024 9h
- Certificate Under Regulation 40(10) Of SEBI(LODR) Regulations, 2015 12 Apr
- Compliance Certificate- Regulation 7(3) Of SEBI(LODR) Regulations, 2015, For The Year Ended March 31, 2024 3 Apr
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 3 Apr
-
Announcement under Regulation 30 (LODR)-Change in Directorate
31 Mar - Completion of tenure of an Independent Director
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT REC
-
May 2023Transcript PPT REC
-
Feb 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
May 2022TranscriptPPT
-
Feb 2022Transcript PPT
-
Oct 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Jul 2020TranscriptPPT
-
May 2020TranscriptPPT
-
Jan 2020TranscriptPPT
-
Nov 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Oct 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Jan 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Sep 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptPPT
Business Segments